Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
113.20
-0.36 (-0.32%)
At close: Jul 24, 2025, 4:00 PM
112.88
-0.32 (-0.28%)
After-hours: Jul 24, 2025, 6:55 PM EDT
Gilead Sciences Employees
Gilead Sciences had 17,600 employees as of December 31, 2024. The number of employees decreased by 400 or -2.22% compared to the previous year.
Employees
17,600
Change (1Y)
-400
Growth (1Y)
-2.22%
Revenue / Employee
$1,632,670
Profits / Employee
$338,920
Market Cap
140.81B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 17,600 | -400 | -2.22% |
Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
Dec 31, 2021 | 14,400 | 800 | 5.88% |
Dec 31, 2020 | 13,600 | 1,800 | 15.25% |
Dec 31, 2019 | 11,800 | 800 | 7.27% |
Dec 31, 2018 | 11,000 | 1,000 | 10.00% |
Dec 31, 2017 | 10,000 | 1,000 | 11.11% |
Dec 31, 2016 | 9,000 | 1,000 | 12.50% |
Dec 31, 2015 | 8,000 | 1,000 | 14.29% |
Dec 31, 2014 | 7,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
GILD News
- 7 hours ago - Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - Business Wire
- 5 days ago - Our Top 10 High Growth Dividend Stocks - July 2025 - Seeking Alpha
- 7 days ago - Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player - GlobeNewsWire
- 8 days ago - Why Merck Is A Better Dividend Stock Than Gilead Sciences - Seeking Alpha
- 8 days ago - GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 10 days ago - WHO recommends Gilead's twice-yearly injection for HIV prevention - Reuters
- 10 days ago - Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025 - Business Wire
- 15 days ago - AHF: Gilead's Greed Costs Latin America HIV Protection - Business Wire